USD 3.5 billion
Vasomotor Symptoms Market Size, Share, Growth Analysis, By Therapy type(Hormonal (Estrogen, Progesterone, Combination, Others)), By Distribution Channel(Hospital pharmacies, Retail pharmacies, Online stores, Others), By Region - Industry Forecast 2024-2031
Report ID:
SQMIG35A2784 |
Region:
Global |
Published Date: July, 2024
Pages:
219
|Tables:
62
|Figures:
69
Vasomotor Symptoms Market Insights
Vasomotor Symptoms Market was valued at USD 3.5 billion in 2022 and is expected to rise from USD 3.74 billion in 2023 to reach a value of USD 6.38 billion by 2031, at a CAGR of 6.90% during the forecast period (2024–2031).
Vasomotor symptoms stand out as the most reported symptoms of menstruation, often manifesting as hot flashes, night sweats, and anemia. These symptoms include bleeding to the neck, face and forehead suddenly, with profuse perspiration. Notably, the frequency and severity of heart palpitations symptoms vary widely among postmenopausal women, with the first two years of menopause being particularly difficult.
The severity of symptoms during this period can be debilitating. Additionally, for some women these symptoms can be permanent, highlighting the varied and individual nature of the menstrual experience Multidimensional neurological symptoms highlight the need for a through which the unique challenges faced by women in this phase of social change are highlighted.
Market Snapshot - 2024–2031
Global Market Size
Largest Segment
Non-Hormonal
Fastest Growth
Non-Hormonal
Growth Rate
6.90% CAGR
Vasomotor Symptoms Market ($ Bn)
Country Share for North America Region (%)
To get more reports on the above market click here to Buy The Report
Vasomotor Symptoms Market Segmental Analysis
The vasomotor symptoms market is segmented into therapy type, distribution channel, and region. Based on therapy type, the market is segmented into Hormonal (Estrogen, Progesterone, Combination, Others), Non-Hormonal (Anti-Depressants, Others). Based on distribution channel, the market is segmented into hospital pharmacies, retail pharmacies, online stores and others. Based on region, the market is segmented into North America, Asia Pacific, Europe, Middle East & Africa, and Latin America.
Analysis by Therapy Type
In 2023, the hormonal segment emerged as the predominant contributor to the vasomotor symptoms market revenue, commanding a substantial share of approximately 65-67%. This dominance is primarily attributed to the prevalence of hormonal therapy as a common and effective treatment option for Vasomotor Symptoms (VMS), particularly among women undergoing menopause-related symptoms.
The non-hormonal segment plays a crucial role in the vasomotor symptoms market, providing alternative treatment options for individuals seeking relief from symptoms associated with menopause and hormonal fluctuations. Unlike hormonal therapies, non-hormonal approaches offer solutions that do not involve the use of estrogen or progesterone. This segment includes diverse treatments such as selective serotonin reuptake inhibitors (SSRIs), selective norepinephrine reuptake inhibitors (SNRIs), gabapentinoids, and lifestyle modifications.
Analysis by Distribution Channel
The hospital pharmacy segment emerges as a dominant force in the market by 2023. This number can be attributed to the growing trend of metal implants, which plays an important role in the availability of multiple pharmacies. Be sure as a calm and regulated environment ensures that patients receive appropriate medications based on their health care needs.
With the increasing popularity of online pharmacies, the online store segment is poised to exhibit rapid growth in the market. These channels have grown tremendously, facilitating not only remote shopping but also reducing its price is also attractive. Notably, initiatives like the one implemented by Tata 1 MG are an example of the trend, where customers can get up to 20% discount on allopathic medicines through online shopping If besides, users stand to gain an additional 5% discount by submitting a doctor’s note. Such models, which combine availability, discounted prices and ease of access to online prescription drugs, are expected to lead to the expansion of online stores in the market.
Vasomotor Symptoms Market By Therapy Type
To get detailed analysis on other segments, Request For Free Sample Report
Vasomotor Symptoms Market Regional Insights
The North America vasomotor symptoms market is valued at US$ 1.6 billion by 2023 and is poised to exhibit a noteworthy growth rate at a compound annual growth rate (CAGR) during the analyzed period. This strong growth is primarily related to syndromes associated with vasomotor issues Besides being due to the readily available knowledge of the availability of relaxing drugs, common symptoms of inflammation widespread around the time of menopause gain market significant impact on development.
Asia Pacific is poised to record the fastest annual growth rate (CAGR) between 2024 and 2031. This growth can be attributed to several factors, including increased education among women and solutions including a designed awareness campaign that illuminates the prevalence of symptoms. Furthermore, there has been a shift in public opinion, menopause is not dismissed as a disease but accepted as an inevitable genetic part of aging.
Vasomotor Symptoms Market By Region
- Largest
- Fastest
To know more about the market opportunities by region and country, click here to
Buy The Complete Report
Vasomotor Symptoms Market Dynamics
Drivers
Increasing Research and Development and Clinical Trials
- Research and development (R&D) programs and clinical trials play an important role in increasing our understanding of the underlying mechanisms of neurological symptoms, including mutations and physiology. This increased understanding could pave the way for more targeted and effective therapies, allowing researchers to work to develop new therapies by further exploring the complexity of neurological disorders through clinical trials contributing to the market’s high compound annual growth rate (CAGR). These trials not only expand the range of treatment options available, but also drive market growth by introducing innovative solutions.
Restraints
Increased Cost of Treatment
- The growth of the market is hindered by the high costs associated with numerous treatment methods. Many market players invest significantly in developing advanced treatment techniques to enhance the recovery process, leading to an increase in overall costs. These substantial investments in research, development, and manufacturing contribute to the elevated expenses associated with various treatment modalities. While these advancements hold the promise of improving patient outcomes and treatment efficacy, the resulting higher costs pose a challenge to market expansion.
Request Free Customization of this report to help us to meet your business objectives.
Vasomotor Symptoms Market Competitive Landscape
The competitive environment of the Vasomotor Symptoms market is dynamic and characterized by the presence of a mix of well-established brands, emerging players, and niche producers. Innovation is a key competitive factor. Leading brands invest in research and development to introduce new flavors, packaging formats, and health-focused variations to cater to changing consumer preferences. They often set the trends in the industry.
Top Player’s Company Profiles
- Astellas Pharma Inc. (Japan)
- Pfizer Inc. (United States)
- Novartis AG (Switzerland)
- Bayer AG (Germany)
- AbbVie Inc. (United States)
- GlaxoSmithKline plc (United Kingdom)
- Johnson & Johnson (United States)
- Merck & Co., Inc. (United States)
- Sanofi S.A. (France)
- Eli Lilly and Company (United States)
- Novo Nordisk A/S (Denmark)
- Teva Pharmaceutical Industries Ltd. (Israel)
- Amgen Inc. (United States)
- Roche Holding AG (Switzerland)
- Bristol-Myers Squibb Company (United States)
- Takeda Pharmaceutical Company Limited (Japan)
- Mylan N.V. (United States)
- Allergan plc (Ireland)
- Endo International plc (Ireland)
- Sun Pharmaceutical Industries Ltd. (India)
Recent Developments
-
In December 2023, Astellas Pharma Inc. announced that the European Commission approved VEOZATM (fezolinetant) 45 mg once daily for treating moderate to severe vasomotor symptoms (VMS) associated with menopause.
-
In July 2023, Mithra Pharmaceuticals and Searchlight Pharma entered into a licensing agreement for Donesta, an investigational drug for treating menopausal symptoms. Data from two multicenter, randomized Phase III trials (C301 – NCT04209543 and C302 – NCT04090957) evaluating Donesta demonstrated a reduction in vasomotor symptoms from baseline and in comparison, to placebo.
Vasomotor Symptoms Key Market Trends
- The introduction of new interventions or the development of new treatments has the potential to increase awareness of vasomotor symptoms (VMS) and the importance of effective treatment This improved awareness can lead to actively seeking women symptom relief has increased, thus creating a larger market for VMS treatment Can Companies that specialize in introducing new products or new treatments for VMS stand to gain a competitive advantage in the market. This advantage is especially important if the drug is to establish itself as the treatment of choice for healthcare professionals and patients.
Vasomotor Symptoms Market SkyQuest Analysis
SkyQuest’s ABIRAW (Advanced Business Intelligence, Research & Analysis Wing) is our Business Information Services team that Collects, Collates, Correlates, and Analyzes the Data collected by means of Primary Exploratory Research backed by robust Secondary Desk research. The market has grown, driven in part by over-the-counter (OTC) products. OTC options are increasingly accepted by patients because of their perceived low side effects. This shift in consumer behavior towards self-care and easy access to OTC products is contributing to the overall expansion of the market. Moreover, major market players are adopting expansion strategies such as mergers and acquisitions, leading to higher market growth. A typical example is the April 2022 acquisition of women’s health specialist Bonafide.
| Report Metric | Details |
|---|---|
| Market size value in 2022 | USD 3.5 billion |
| Market size value in 2031 | USD 6.38 billion |
| Growth Rate | 6.90% |
| Base year | 2023 |
| Forecast period | 2024–2031 |
| Forecast Unit (Value) | USD Billion |
| Segments covered |
|
| Regions covered | North America (US, Canada), Europe (Germany, France, United Kingdom, Italy, Spain, Rest of Europe), Asia Pacific (China, India, Japan, Rest of Asia-Pacific), Latin America (Brazil, Rest of Latin America), Middle East & Africa (South Africa, GCC Countries, Rest of MEA) |
| Companies covered |
|
| Customization scope | Free report customization with purchase. Customization includes:-
|
To get a free trial access to our platform which is a one stop solution for all your data requirements for quicker decision making. This platform allows you to compare markets, competitors who are prominent in the market, and mega trends that are influencing the dynamics in the market. Also, get access to detailed SkyQuest exclusive matrix.
Buy The Complete Report to read the analyzed strategies adopted by the top vendors either to retain or gain market share
Table Of Content
Executive Summary
Market overview
- Exhibit: Executive Summary – Chart on Market Overview
- Exhibit: Executive Summary – Data Table on Market Overview
- Exhibit: Executive Summary – Chart on Vasomotor Symptoms Market Characteristics
- Exhibit: Executive Summary – Chart on Market by Geography
- Exhibit: Executive Summary – Chart on Market Segmentation
- Exhibit: Executive Summary – Chart on Incremental Growth
- Exhibit: Executive Summary – Data Table on Incremental Growth
- Exhibit: Executive Summary – Chart on Vendor Market Positioning
Parent Market Analysis
Market overview
Market size
- Market Dynamics
- Exhibit: Impact analysis of DROC, 2021
- Drivers
- Opportunities
- Restraints
- Challenges
- Exhibit: Impact analysis of DROC, 2021
- SWOT Analysis
KEY MARKET INSIGHTS
- Technology Analysis
- (Exhibit: Data Table: Name of technology and details)
- Pricing Analysis
- (Exhibit: Data Table: Name of technology and pricing details)
- Supply Chain Analysis
- (Exhibit: Detailed Supply Chain Presentation)
- Value Chain Analysis
- (Exhibit: Detailed Value Chain Presentation)
- Ecosystem Of the Market
- Exhibit: Parent Market Ecosystem Market Analysis
- Exhibit: Market Characteristics of Parent Market
- IP Analysis
- (Exhibit: Data Table: Name of product/technology, patents filed, inventor/company name, acquiring firm)
- Trade Analysis
- (Exhibit: Data Table: Import and Export data details)
- Startup Analysis
- (Exhibit: Data Table: Emerging startups details)
- Raw Material Analysis
- (Exhibit: Data Table: Mapping of key raw materials)
- Innovation Matrix
- (Exhibit: Positioning Matrix: Mapping of new and existing technologies)
- Pipeline product Analysis
- (Exhibit: Data Table: Name of companies and pipeline products, regional mapping)
- Macroeconomic Indicators
COVID IMPACT
- Introduction
- Impact On Economy—scenario Assessment
- Exhibit: Data on GDP - Year-over-year growth 2016-2022 (%)
- Revised Market Size
- Exhibit: Data Table on Vasomotor Symptoms Market size and forecast 2021-2027 ($ million)
- Impact Of COVID On Key Segments
- Exhibit: Data Table on Segment Market size and forecast 2021-2027 ($ million)
- COVID Strategies By Company
- Exhibit: Analysis on key strategies adopted by companies
MARKET DYNAMICS & OUTLOOK
- Market Dynamics
- Exhibit: Impact analysis of DROC, 2021
- Drivers
- Opportunities
- Restraints
- Challenges
- Exhibit: Impact analysis of DROC, 2021
- Regulatory Landscape
- Exhibit: Data Table on regulation from different region
- SWOT Analysis
- Porters Analysis
- Competitive rivalry
- Exhibit: Competitive rivalry Impact of key factors, 2021
- Threat of substitute products
- Exhibit: Threat of Substitute Products Impact of key factors, 2021
- Bargaining power of buyers
- Exhibit: buyers bargaining power Impact of key factors, 2021
- Threat of new entrants
- Exhibit: Threat of new entrants Impact of key factors, 2021
- Bargaining power of suppliers
- Exhibit: Threat of suppliers bargaining power Impact of key factors, 2021
- Competitive rivalry
- Skyquest special insights on future disruptions
- Political Impact
- Economic impact
- Social Impact
- Technical Impact
- Environmental Impact
- Legal Impact
Market Size by Region
- Chart on Market share by geography 2021-2027 (%)
- Data Table on Market share by geography 2021-2027(%)
- North America
- Chart on Market share by country 2021-2027 (%)
- Data Table on Market share by country 2021-2027(%)
- USA
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Canada
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Europe
- Chart on Market share by country 2021-2027 (%)
- Data Table on Market share by country 2021-2027(%)
- Germany
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Spain
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- France
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- UK
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Rest of Europe
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Asia Pacific
- Chart on Market share by country 2021-2027 (%)
- Data Table on Market share by country 2021-2027(%)
- China
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- India
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Japan
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- South Korea
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Rest of Asia Pacific
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Latin America
- Chart on Market share by country 2021-2027 (%)
- Data Table on Market share by country 2021-2027(%)
- Brazil
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Rest of South America
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Middle East & Africa (MEA)
- Chart on Market share by country 2021-2027 (%)
- Data Table on Market share by country 2021-2027(%)
- GCC Countries
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- South Africa
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Rest of MEA
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
KEY COMPANY PROFILES
- Competitive Landscape
- Total number of companies covered
- Exhibit: companies covered in the report, 2021
- Top companies market positioning
- Exhibit: company positioning matrix, 2021
- Top companies market Share
- Exhibit: Pie chart analysis on company market share, 2021(%)
- Total number of companies covered
Methodology
For the Vasomotor Symptoms Market, our research methodology involved a mixture of primary and secondary data sources. Key steps involved in the research process are listed below:
1. Information Procurement: This stage involved the procurement of Market data or related information via primary and secondary sources. The various secondary sources used included various company websites, annual reports, trade databases, and paid databases such as Hoover's, Bloomberg Business, Factiva, and Avention. Our team did 45 primary interactions Globally which included several stakeholders such as manufacturers, customers, key opinion leaders, etc. Overall, information procurement was one of the most extensive stages in our research process.
2. Information Analysis: This step involved triangulation of data through bottom-up and top-down approaches to estimate and validate the total size and future estimate of the Vasomotor Symptoms Market.
3. Report Formulation: The final step entailed the placement of data points in appropriate Market spaces in an attempt to deduce viable conclusions.
4. Validation & Publishing: Validation is the most important step in the process. Validation & re-validation via an intricately designed process helped us finalize data points to be used for final calculations. The final Market estimates and forecasts were then aligned and sent to our panel of industry experts for validation of data. Once the validation was done the report was sent to our Quality Assurance team to ensure adherence to style guides, consistency & design.
Analyst Support
Customization Options
With the given market data, our dedicated team of analysts can offer you the following customization options are available for the Vasomotor Symptoms Market:
Product Analysis: Product matrix, which offers a detailed comparison of the product portfolio of companies.
Regional Analysis: Further analysis of the Vasomotor Symptoms Market for additional countries.
Competitive Analysis: Detailed analysis and profiling of additional Market players & comparative analysis of competitive products.
Go to Market Strategy: Find the high-growth channels to invest your marketing efforts and increase your customer base.
Innovation Mapping: Identify racial solutions and innovation, connected to deep ecosystems of innovators, start-ups, academics, and strategic partners.
Category Intelligence: Customized intelligence that is relevant to their supply Markets will enable them to make smarter sourcing decisions and improve their category management.
Public Company Transcript Analysis: To improve the investment performance by generating new alpha and making better-informed decisions.
Social Media Listening: To analyze the conversations and trends happening not just around your brand, but around your industry as a whole, and use those insights to make better Marketing decisions.
USA (+1) 351-333-4748
